The pharmaceutical and healthcare sector remained actively tracked by investors on May 5, with the NIFTY Pharmaindex witnessing mixed sentiment amid broader market volatility driven by global crude oil concerns and foreign fund outflows. 

Despite weakness in the broader markets, select pharma and healthcare companies continued to attract investor attention due to regulatory approvals, strong earnings momentum, and expansion initiatives. 

Among the major developments, Lupin Limited received USFDA approval for its generic version of Ravicti Oral Liquid, strengthening its specialty portfolio in the US market. Meanwhile, OneSource Specialty Pharma Limitedannounced that its partner received Health Canada approval for a generic semaglutide injection, further boosting interest in peptide and injectable-focused CDMO players.

Wockhardt Limited emerged among the top-performing pharma-related stocks after reporting a strong operational turnaround and improved quarterly performance, with its shares gaining sharply during the session. 

Market analysts indicated that while generic drugmakers continue to face pricing pressures in global markets, diversified pharma players with specialty products, CDMO capabilities, and strong domestic businesses are likely to remain relatively resilient. Hospital and healthcare delivery companies also continued to show stable growth trends backed by rising healthcare demand and diagnostics expansion. 

Digital health, preventive diagnostics, specialty therapies, and biologics remained among the key themes shaping investor sentiment across the healthcare ecosystem.